When Cognition Was Assessed After Sequential Oral CBD and THC
Testing occurred later in the oral dosing session: approximately 205 minutes after CBD or placebo, following THC or placebo given thirty minutes after the first treatment. That schedule addresses a specific assessment window.
Reconstruct both dosing clocks
In the four-group experiment, the first capsules contained 800 mg CBD or matching placebo. Thirty minutes later, participants received 20 mg THC or its placebo. Blood collection for THC analysis occurred approximately 205 minutes after the first treatment, followed by neuropsychological assessments. This corresponds to about 175 minutes after the second treatment, before allowing for the time needed to complete the tasks.
One window cannot describe every phase
Baseline tests were administered the preceding day, and testing was repeated the following day. The interventional assessment was not continuous monitoring of cognition throughout absorption and elimination. The design therefore cannot establish the precise onset, maximum or resolution of every cognitive effect. Nor does it determine the response to CBD taken after THC.
Preserve timing in an evidence claim
The reported failure of pretreatment to mitigate the measured effects applies to the studied sequence and testing context. It does not supply an all-day profile or a universal duration of impairment. Oral dosing, a small selected male sample and between-group comparisons are relevant limitations when applying the findings to a different sequence or collection time.
Related analysis: the oral CBD pretreatment trial.
Research cited
Woelfl and colleagues (2020). Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. DOI: 10.3389/fpsyt.2020.576877.
